|
|
|
|
Managing Directors |
Jeff Himawan, PhD, has over 20 years of experience as a scientist,
entrepreneur and venture capitalist. He began his industrial career in
1987 as a bench scientist at Genzyme Corporation. In 1996, Dr. Himawan
co-founded Seed-One Ventures, a venture capital firm that specializes in
the initial formation, financing, and early operational development of
technology-based companies. As a Managing Director at Seed-One Ventures,
he led the formation and management of
Elusys Therapeutics, a Fund IV
company.
Dr. Himawan joined Essex Woodlands in 2001. He serves on the Board of
Directors of
Receptor BioLogix,
MediciNova,
Light Sciences
Oncology,
Ception Therapeutics,
Horizon
Therapeutics and
Symphogen.
Dr. Himawan holds a Bachelor of Science degree from the Massachusetts
Institute of Technology and a PhD degree from Harvard University. He has
written several patents in the fields of wireless communications,
biotechnology, and protein chemistry. |
|
|
 |
|
|
|
